Core Insights - The overall myopia rate among children and adolescents in China reached 51.9% in 2022, with specific rates of 14.5% for 6-year-olds, 36% for elementary school students, 71.6% for middle school students, and 81% for high school students [2] Company Strategy - The company aims to raise awareness of its treatment plan to over 20 million people and ensure that over 1 million children receive timely and appropriate medication this year [2] - The company will implement a comprehensive multi-channel sales strategy, focusing on collaboration with retail channels and continuing academic promotion to build a network for myopia prevention and control [2]

Core Viewpoint - The company is focusing on a multi-channel marketing strategy to enhance the accessibility and patient experience of its atropine product, which is primarily sold through offline channels, accounting for over 50% of sales [2]. Group 1: Sales Strategy - Atropine sales are currently dominated by offline channels, with over 50% of sales coming from this segment [2]. - The company is implementing a comprehensive marketing strategy that includes partnerships with professional associations, e-commerce platforms, and pharmacy chains [2]. Group 2: Product Accessibility and Education - The company is committed to improving product accessibility and patient medication experience through ongoing academic promotion and public education on myopia prevention [2]. - Efforts are being made to enhance the pharmaceutical service system to support these initiatives [2].

（文章来源：每日经济新闻） 兴齐眼药（300573.SZ）11月13日在投资者互动平台表示，目前我司与海外合作方的合作处于前期沟通 阶段，后续达到信息披露节点时，我们将严格按照相关规定及时履行信息披露义务。关于销售的具体情 况，请您关注公司定期报告。 每经AI快讯，有投资者在投资者互动平台提问：这次双十一销量怎么样？有没有出海BD考虑？ ...

Core Viewpoint - The company currently has four production lines certified for the production of 0.01% atropine sulfate eye drops, which are sufficient to meet current market demand. Future capacity adjustments will be made based on market demand changes [1]. Group 1 - The company has four production lines with GMP certification for 0.01% atropine sulfate eye drops [1]. - Current production capacity is adequate to satisfy market demand [1]. - The company plans to adjust production capacity and layout according to changes in market demand in the future [1].

Core Viewpoint - The company has four production lines certified for GMP to produce 0.01% atropine sulfate eye drops, and its current production capacity meets market demand [1] Group 1 - The company has obtained GMP certification for four production lines [1] - The production capacity is currently sufficient to meet market demand [1]

Group 1 - The ophthalmology medical concept sector rose by 1.24%, ranking 7th among concept sectors, with 30 stocks increasing in value, including notable gainers such as People's Tongtai, Zhongsheng Pharmaceutical, and ST Zhongzhu, which hit the daily limit up [1] - The top gainers in the sector included Guanhao Biological, Innovative Medical, and Baijin Medical, with increases of 7.47%, 5.67%, and 4.75% respectively [1] - The sector experienced a net inflow of 882 million yuan from main funds, with 28 stocks receiving net inflows, and 5 stocks seeing inflows exceeding 50 million yuan, led by Zhongsheng Pharmaceutical with a net inflow of 436 million yuan [1] Group 2 - The top stocks by net inflow ratio included People's Tongtai, Jianghe Group, and ST Zhongzhu, with net inflow ratios of 36.50%, 22.79%, and 18.25% respectively [2] - Zhongsheng Pharmaceutical had a daily increase of 10.02% with a turnover rate of 17.65%, while Heng Rui Pharmaceutical and Xingqi Eye Medicine had net inflows of 192 million yuan and 100 million yuan respectively [2][3] - The overall performance of the ophthalmology medical sector was supported by significant capital inflows, indicating strong investor interest [1][2]

Core Points - The company announced the results of the fourth vesting period for its 2021 restricted stock incentive plan, with a total of 1,080,582 shares vesting, representing 0.44% of the company's total share capital before vesting [1] - A total of 77 individuals are involved in this vesting event, with the vesting date set for November 7, 2025 [1] - The shares from this vesting will be listed and tradable on November 7, 2025, and there is no lock-up period for these restricted shares [1]

3、本次第二类限制性股票上市流通日为 2025 年 11 月 7 日，本次归属的限 制性股票不设限售期。 证券代码：300573 证券简称：兴齐眼药 公告编号：2025-056 沈阳兴齐眼药股份有限公司 关于 2021 年限制性股票激励计划 第四个归属期归属结果暨股份上市公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、本次第二类限制性股票的归属日为 2025 年 11 月 7 日。 2、本次第二类限制性股票的归属数量为 1,080,582 股，占归属前公司总股 本的 0.44%，归属人数为 77 人。 沈阳兴齐眼药股份有限公司于 2025 年 9 月 28 日召开的第五届董事会第十一 次会议审议通过了《关于公司 2021 年限制性股票激励计划第四个归属期归属条 件成就的议案》。近日，公司申请办理了 2021 年限制性股票激励计划第四个归属 期的登记工作，具体情况公告如下： 一、本次激励计划实施情况概要 （一）2021年限制性股票激励计划简介 公司分别于2021年8月26日召开的第四届董事会第五次会议及2021年9月13 日召开的202 ...

截至2025年10月31日收盘，兴齐眼药(300573)报收于80.21元，下跌3.73%，换手率12.22%，成交量23.04 万手，成交额18.69亿元。 董秘： 尊敬的投资者，您好。未来这两款产品上市后，将进一步优化公司近视防控产品矩阵，持续为 儿童青少年提供更全面的近视防控解决方案。感谢您的关注。 投资者： 您好，公司不同浓度硫酸阿托品滴眼液（0.02%和 0.04%）在药品审评中心（CDE）审评中， 请问评审通过了吗？该浓度滴眼液和0.01%浓度市场规模是否更大? 董秘： 尊敬的投资者，您好。公司不同浓度硫酸阿托品滴眼液（0.02%和 0.04%）目前正处于审评阶 段，后续达到信息披露标准时，公司将按照法律法规及相关规定，及时、准确地履行信息披露义务。不 同浓度的硫酸阿托品滴眼液在临床使用过程中能够更好的满足不同近视人群对近视控制的需求。 谢 谢。 投资者： 公司2025年三季度业绩非常好超预期，公司本次定增完成后是否考虑跟随国家战略去香港新 发H股？ 董秘： 尊敬的投资者，您好。公司暂无相关计划，感谢您的关注。 董秘最新回复 投资者： 请问，公司不同浓度硫酸阿托品滴眼液（0.02%和 0.04%） ...

Core Viewpoint - Xingqi Eye Pharmaceutical is a leading company in the domestic ophthalmic drug sector, focusing on research and development, with a competitive product lineup in the market [1] Financial Performance - For Q3 2025, Xingqi Eye Pharmaceutical reported revenue of 1.904 billion yuan, ranking 35th out of 110 in the industry, significantly lower than the top two competitors, East China Pharmaceutical (32.664 billion yuan) and Fosun Pharmaceutical (29.393 billion yuan), but above the industry average of 280 million yuan and median of 83.8 million yuan [2] - The net profit for the same period was 599 million yuan, ranking 14th in the industry, again lower than the leaders, but above the industry average of 299 million yuan and median of 78.29 million yuan [2] Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 23.24%, down from 25.53% year-on-year and below the industry average of 35.26%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 81.33%, an increase from 78.38% year-on-year and above the industry average of 57.17%, reflecting robust profitability [3] Executive Compensation - Chairman Liu Jidong's salary for 2024 was 6.001 million yuan, a slight increase from 6 million yuan in 2023 [4] - General Manager Gao E's salary for 2024 was 2.3202 million yuan, up from 2.079 million yuan in 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 16.85% to 54,100, with an average holding of 3,480.23 shares, a decrease of 14.42% [5] Growth Projections - According to Huazheng Securities, Xingqi Eye Pharmaceutical is expected to achieve revenues of 2.76 billion yuan, 3.65 billion yuan, and 4.57 billion yuan from 2025 to 2027, with respective year-on-year growth rates of 41.8%, 32.5%, and 25.1% [6] - Net profits for the same period are projected to be 760 million yuan, 1.1 billion yuan, and 1.43 billion yuan, with year-on-year growth rates of 123.7%, 45.2%, and 30.5% [6] Clinical Development - The company is advancing its pipeline with several new ophthalmic drugs, including SQ-129 vitreous sustained-release injection and SQ-22031 eye drops, which are in clinical trials [6][7] - The sales of core products, particularly low-concentration atropine eye drops, are expected to continue to grow [7]